NovoCure Ltd

NVCR Nasdaq CIK: 0001645113

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Large accelerated filer
Country Jersey
Business Address NO. 4 THE FORUM, ST. HELIER, ,
Mailing Address NO. 4 THE FORUM, ST. HELIER, ,
Phone 44 (0)15 3475 6700
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

$880.61M
Total Liabilities
$441.17M
Stockholders' Equity
$-1.56
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 26, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC

Annual Reports

10-K February 26, 2026
  • Pioneering Tumor Treating Fields (TTFields) technology for aggressive cancers, with flagship product Optune approved for GBM and MPM.
  • Strong financial health with $950 million in cash and equivalents and no significant long-term debt by year-end 2023.
View Analysis

Material Events

8-K Legal Issue February 5, 2026
High Impact
  • NovoCure Ltd is pioneering electric field therapy (TTFields) for cancer, an innovative treatment.
  • The CMS revocation was due to an 'administrative process issue,' not issues with the effectiveness, safety, or quality of NovoCure's treatment.
View Analysis

Insider Trading

STRONG SELL 7 insiders 17 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.